SUMMARY OF STUDIES
- Reduces aggregation of alpha synuclein
- Reversal of Parkinson’s Symptoms
- Non Toxic to Nigral Dopamine Cells
- Slow Washout Period
- Positive results in marmoset models
- Oral, IV, IM Delivery
- Rapid Onset of Action
- Possible Neuro-protective Properties
IPX-750 has shown very significant effects in reducing the aggregation/misfolding of the alpha-synuclein protein in studies at the University Of Alabama Birmingham (UAB) with the protein being furnished by the Mayo Clinic Jacksonville.
IPX-750 attenuates α-synuclein oligomerization.
Percent reduction in α-synuclein oligomerization, a condition that leads to Parkinson disease, was measured in response to IPX-750 treatment.
These combined results suggest the following:
1. That stereospecific glyconconjugation may be an effective intervention to improve penetrability of drugs through the blood brain barrier.
2. Treatment with IPX-750 in vitro did not show evidence for neurotoxicity.
3. IPX-750 possesses possible neuroprotective effects on substantia nigral neurons in rodent models.
4. IPX- 750 possesses dopaminergic properties and exerts anti-parkinsonian effects in three different Parkinson’s disease rodent models and with marmoset models.
5. A Reduction and prevention of the aggregation/misfolding of the alpha synuclein protein, suggesting therapeutic potential for this new class of drugs in treating Parkinson’s disease and other dopamine deficiency diseases.